

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Peter A. McCullough MD, MPH , Ronan J. Kelly MD , Gaetano Ruocco MD , Edgar Lerma MD , James Tumlin MD , Kevin Wheelan MD , Nevin Katz MD , Norman E. Lepor MD , Kris Vijay MD , Harvey Carter MD , Bhupinder Singh MD , Sean P. McCullough BS , Brijesh K. Bhambi MD , Alberto Palazzuoli MD, PhD , Gaetano M De Ferrari MD, PhD , Gregory Milligan MD, MPH , Taimur Safder MD, MPH , Kristen M. Tecson PhD , Dee Dee Wang MD , McKinnon MD , William W. O'Neill MD , Marcus Zervos MD , Harvey A. Risch MD, PhD



PII: S0002-9343(20)30673-2
DOI: <https://doi.org/10.1016/j.amjmed.2020.07.003>
Reference: AJM 15873

To appear in: *The American Journal of Medicine*

Please cite this article as: Peter A. McCullough MD, MPH , Ronan J. Kelly MD , Gaetano Ruocco MD , Edgar Lerma MD , James Tumlin MD , Kevin Wheelan MD , Nevin Katz MD , Norman E. Lepor MD , Kris Vijay MD , Harvey Carter MD , Bhupinder Singh MD , Sean P. McCullough BS , Brijesh K. Bhambi MD , Alberto Palazzuoli MD, PhD , Gaetano M De Ferrari MD, PhD , Gregory Milligan MD, MPH , Taimur Safder MD, MPH , Kristen M. Tecson PhD , Dee Dee Wang MD , McKinnon MD , William W. O'Neill MD , Marcus Zervos MD , Harvey A. Risch MD, PhD , Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection, *The American Journal of Medicine* (2020), doi: <https://doi.org/10.1016/j.amjmed.2020.07.003>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2
(COVID-19) Infection

Peter A. McCullough, MD, MPH,^{1,2,3} Ronan J. Kelly, MD,¹ Gaetano Ruocco, MD,⁴ Edgar Lerma, MD,⁵ James Tumlin, MD,⁶ Kevin Wheelan, MD,^{1,2,3} Nevin Katz, MD,⁷ Norman E. Lepor, MD,⁸ Kris Vijay, MD,⁹ Harvey Carter, MD,¹⁰ Bhupinder Singh, MD,¹¹ Sean P. McCullough, BS,¹² Brijesh K. Bhambi, MD,¹³ Alberto Palazzuoli, MD, PhD,¹⁴ Gaetano M De Ferrari, MD, PhD,¹⁵ Gregory Milligan, MD, MPH,¹ Taimur Safder, MD, MPH,¹ Kristen M. Tecson, PhD,² Dee Dee Wang, MD,¹⁶ McKinnon, MD,¹⁶ William W. O'Neill, MD,¹⁶ Marcus Zervos, MD,¹⁶ Harvey A. Risch, MD, PhD¹⁷

¹Baylor University Medical Center, ²Baylor Heart and Vascular Institute, ³Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, ⁴Cardiology Division, Regina Montis Regalis Hospital, Mondovì, Cuneo, Italy, ⁵Christ Advocate Medical Center, Chicago, IL ⁶Emory University School of Medicine, Atlanta, GA, ⁷Johns Hopkins School of Medicine, Baltimore, MD, ⁸Cedars Sinai Medical Center, Los Angeles, CA, ⁹Abrazo Arizona Heart Hospital, Abrazo Health System, Phoenix, Arizona, Phoenix, AZ, ¹⁰Carter Eye Center, Dallas, TX ¹¹Cardiorenal Society of America, Phoenix, AZ, ¹²University of Texas McGovern Medical School, Houston, TX, ¹³Bakersfield Heart Hospital, Bakersfield, CA, ¹⁴University of Siena, Le Scotte Hospital Viale Bracci Siena Italy, ¹⁵University of Torino, Torino, Italy, ¹⁶Henry Ford Hospital, Detroit MI, Yale University School of Public Health, New Haven, CT¹⁷

Address for Correspondence

Peter A. McCullough, MD, MPH

Baylor Heart and Vascular Institute

621 N. Hall St, H030, Dallas, TX USA 75226

peteramccullough@gmail.com

Word Count: 3000

Funding source(s): none related

Conflict of interest statement for all authors: nothing to disclose

All authors had access to the data and a role in writing the manuscript

Running head: Outpatient Treatment for COVID-19

Journal Pre-proof

Abstract

Approximately 9 months of the SARS-CoV-2 virus spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital. In the absence of clinical trial results, physicians must use what has been learned about the pathophysiology of SARS-CoV-2 infection in determining early outpatient treatment of the illness with the aim of preventing hospitalization or death. This paper outlines key pathophysiological principles that relate to the patient with early infection treated at home. Therapeutic approaches based on these principles include: 1) reduction of reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4) antiplatelet/antithrombotic therapy 5) administration of oxygen, monitoring, and telemedicine. Future randomized trials testing the principles and agents discussed in this paper will undoubtedly refine and clarify their individual roles, however we emphasize the immediate need for management guidance in the setting of widespread hospital resource consumption, morbidity, and mortality.

Key words: SARS-CoV-2; COVID-19; hospitalization; critical care; mortality; epidemiology; ambulatory treatment; antiviral; anti-inflammatory; anticoagulant

The pandemic of SARS-CoV-2 (COVID-19), is rapidly expanding across the world with each country and region developing distinct epidemiologic patterns in terms of frequency, hospitalization, and death. There has been considerable focus on two major areas of response to the pandemic: 1) containment of the spread of infection, 2) reducing inpatient mortality. These efforts while well-justified, have not addressed the ambulatory patient with COVID-19 who is at risk for hospitalization and death. The current epidemiology of rising COVID-19 hospitalizations serves as a strong impetus for an attempt at treatment in the days or weeks before a hospitalization occurs.(1) Most patients who arrive to the hospital by emergency medical services with COVID-19 do not initially require forms of advanced medical care.(2) Once hospitalized, ~25% require mechanical ventilation, advanced circulatory support, or renal replacement therapy. Hence, it is conceivable that some if not a majority of hospitalizations could be avoided with a treat-at-home first approach with appropriate telemedicine monitoring and access to oxygen and therapeutics.(3)

As in all areas of medicine, the large randomized, placebo-controlled, parallel group clinical trial in appropriate patients at risk with meaningful outcomes is the theoretical gold standard for recommending therapy. These standards are not sufficiently rapid or responsive to COVID-19 pandemic.(4) One could argue the results of definitive trials were needed at the outset of the pandemic, and certainly are needed now with over 1 million cases and 500,000 deaths worldwide.(5) Because COVID-19 is highly communicable, many ambulatory clinics do not care for patients in face-to-face visits and these patients are commonly declined by pharmacies, laboratories, and imaging centers. On May 14, 2020, after about 1 million cases and 90,000 deaths in the US had already occurred, the National Institutes of Health announced it was launching

an outpatient trial of hydroxychloroquine (HCQ) and azithromycin in COVID-19.(6) A month later the agency announced it was closing the trial due to lack of enrollment with only 20 of 2000 patients recruited.(7) No safety concerns were associated with the trial. This effort serves as the best current working example of the lack of feasibility of outpatient trials for COVID-19. It is also a strong signal that future ambulatory trial results are not imminent or likely to report soon enough to have a significant public health impact on clinical outcomes.(8)

If clinical trials are not feasible or will not deliver timely guidance to clinicians or patients, then other scientific information bearing upon medication efficacy and safety needs to be examined. Cited in this paper, more than a dozen studies of various designs have examined a range of existing medications. Thus, in the context of present knowledge, given the severity of the outcomes and the relative availability, cost, and toxicity of the therapy, each physician and patient must make a choice: watchful waiting in self-quarantine or empiric treatment with the aim of reducing hospitalization and death. Since COVID-19 expresses a wide spectrum of illness progressing from asymptomatic to symptomatic infection to fulminant adult respiratory distress syndrome and multi-organ system failure, there is a need to individualize therapy according to what has been learned about the pathophysiology of human SARS-CoV-2 infection.(9) It is beyond the scope of this paper to review every preclinical and retrospective study of proposed COVID-19 therapy. Hence the agents proposed are those that have appreciable clinical support and are feasible for administration in the ambulatory setting. SARS-CoV-2 as with many infections, may be amenable to therapy early in its course but is probably not responsive to the same treatments very late in the hospitalized and terminal stages of illness.(10)

For the ambulatory patient with recognized early signs and symptoms of COVID-19, often with nasal real-time reverse transcription or oral antigen testing pending, the following four principles could be deployed in a layered and escalating manner depending on clinical manifestations of COVID-19 like illness(11) and confirmed infection: 1) reduction of reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4) antiplatelet/antithrombotic therapy. Because the results of testing could take up to a week to return, treatment can be started before the results are known. For patients with cardinal features of the syndrome (fever, body aches, nasal congestion, loss of taste and smell, etc) and suspected false negative testing, treatment can be the same as those with confirmed COVID-19.(11) Future randomized trials are expected to confirm, reject, refine, and expand these principles. In this paper, they are set forth in emergency response to the growing pandemic as shown in Figure 1.

Control of Contagion

A major goal of self-quarantine is control of contagion.(12) Many sources of information suggest the main place of viral transmission occurs in the home.(13) Facial covering for all contacts within the home as well as frequent use of hand sanitizer and hand washing is mandatory. Sterilizing surfaces such as countertops, door handles, phones, and other devices is advised. When possible, other close contacts can move out of the domicile and temporary stay with others not ill with SARS-CoV-2. Findings from multiple studies indicate that policies concerning control of the spread SARS-CoV-2 are effective and extension into the home as the most frequent site of viral transfer is paramount.(14)

Reduction of Self-Reinoculation

It is well recognized that COVID-19 exists outside the human body in a bioaerosol of airborne particles and droplets. Since exhaled air in an infected person is considered to be “loaded” with inoculum, each exhalation and inhalation is effectively reinoculation.(15) In hospitalized patients, negative pressure is applied to the room air largely to reduce spread outside of the room. We propose that fresh air could reduce reinoculation and potentially reduce the severity of illness and possibly reduce household spread during quarantine. This calls for open windows, fans for aeration, or spending long periods of time outdoors away from others with no face covering in order to disperse and not re-inhale the viral bioaerosol.

Combination Antiviral Therapy

Rapid and amplified viral replication is the hallmark of most acute viral infections. By reducing the rate, quantity, or duration of viral replication, the degree of direct viral injury to the respiratory epithelium, vasculature, and organs may be lessened.(16) Additionally, secondary processes that depend on viral stimulation including activation of inflammatory cells, cytokines, and coagulation could potentially be lessened if viral replication is attenuated. Because no form of readily available medication has been designed specifically to inhibit SARS-CoV-2 replication, two or more of the nonspecific agents listed below can be entertained. None of the approaches listed below have

specific regulatory approved advertising labels for their manufacturers, thus all would be appropriately considered acceptable “off-label” use.(17)

Zinc Lozenges and Zinc Sulfate

Zinc is a known inhibitor of coronavirus replication. Clinical trials of zinc lozenges in the common cold have demonstrated modest reductions in the duration and or severity of symptoms.(18) By extension, this readily available nontoxic therapy could be deployed at the first signs of COVID-19.(19) Zinc lozenges can be administered five times a day for up to five days and extended if needed if symptoms persist. The amount of elemental zinc lozenges is <25% of that in a single 220 mg zinc sulfate daily tablet. This dose of zinc sulfate has been effectively used in combination with antimalarials in early treatment of high-risk outpatients with COVID-19.(20)

Antimalarials

Hydroxychloroquine (HCQ), is an antimalarial/anti-inflammatory drug that impairs endosomal transfer of virions within human cells. HCQ is also a zinc ionophore that conveys zinc intracellularly to block the SARS-CoV-2 RNA-dependent RNA polymerase which is the core enzyme of the virus replication.(21) The currently completed retrospective studies and randomized trials have generally shown these findings: 1) when started late in the hospital course and for short durations of time, antimalarials

appear to be ineffective, 2) when started earlier in the hospital course, for progressively longer durations and in outpatients, antimalarials may reduce the progression of disease, prevent hospitalization, and are associated with reduced mortality. (22,23,24,25) In a retrospective inpatient study of 2541 patients hospitalized with COVID-19, therapy associated with an adjusted reduction in mortality was HCQ alone, HR=0.34 (95% CI 0.25-0.46), $p < 0.001$, and HCQ with azithromycin, HR=0.29, 95% CI 0.22-0.40, $p < 0.001$. (23) HCQ was approved by the U.S. Food and Drug Administration in 1955, has been used by hundreds of millions of people worldwide since then, is sold over the counter in many countries and has a well characterized safety profile that should not raise undue alarm. (25,26) While asymptomatic QT prolongation is a well-recognized and infrequent (<1%) complication of HCQ it is possible that in the setting of acute illness symptomatic arrhythmias could develop. Data safety and monitoring boards have not declared safety concerns in any clinical trial published to date. Rare patients with a personal or family history of prolonged QT syndrome, those on additional QT prolonging, contraindicated drugs (e.g. dofetilide, sotalol), should be treated with caution and a plan to monitor the QTc in the ambulatory setting. A typical HCQ regimen is 200 mg bid for 5 days and extended to 30 days for continued symptoms. A minimal sufficient dose of HCQ should be used, because in excessive doses the drug can interfere with early immune response to the virus.

Azithromycin

Azithromycin is a commonly used macrolide antibiotic that has antiviral properties mainly attributed to reduced endosomal transfer of virions as well as established anti-

inflammatory effects.(27) It has been commonly utilized in COVID-19 studies initially based upon a French reports demonstrating markedly reduced durations of viral shedding, fewer hospitalizations, and reduced mortality combination with HCQ as compared to those untreated.(28,29) In the large inpatient study (n=2451) discussed above, those who received azithromycin alone had an adjusted hazard ratio for mortality of 1.05, 95% CI 0.68-1.62, p=0.83.(23) The combination of HCQ and azithromycin has been used as standard-of-care in other contexts as a standard of care in more than 300,000 older adults with multiple comorbidities.(30) This agent is well tolerated and like HCQ can prolong the QTc in <1% of patients. The same safety precautions for HCQ listed above could be extended to azithromycin with or without HCQ. Azithromycin provides additional coverage of bacterial upper respiratory pathogens that could potentially play a role in concurrent or secondary infection. Thus, this agent can serve as a safety net for COVID-19 patients against clinical failure of the bacterial component of community acquired pneumonia.(32) The same safety precautions for HCQ listed above could be extended to azithromycin with or without HCQ. Because both HCQ and AZ have small but potentially additive risks of QTc prolongation, patients with known or suspected arrhythmias or taking contraindicated medications or should have more thorough workup (review of baseline electrocardiogram, imaging studies, etc) before receiving these two together. One of many dosing schemes is 250 mg po bid for 5 days and may extend to 30 days for persistent symptoms or evidence of bacterial superinfection.

Doxycycline

Doxycycline is another common antibiotic with multiple intracellular effects that may reduce viral replication, cellular damage, and expression of inflammatory factors.(33,34) This drug has no effect on cardiac conduction and has the main caveat of gastrointestinal upset and esophagitis. As with azithromycin, doxycycline has the advantage of offering antibacterial coverage for superimposed bacterial infection in the upper respiratory tract. Doxycycline has a high degree of activity against many common respiratory pathogens including *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, anaerobes such as *Bacteroides* and anaerobic/microaerophilic streptococci and atypical agents like *Legionella*, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*.(34) One of many dosing schemes is 200 mg po followed by 100 mg po bid for 5 days and may extend to 30 days for persistent symptoms or evidence of bacterial superinfection. Doxycycline may be useful with HCQ for patients in whom the HCQ-AZ combination is not desired.

Favipiravir

Favipiravir an oral selective inhibitor of RNA-dependent RNA polymerase, is approved for ambulatory use in COVID-19 in Russia, India, and other countries outside of the United States.(35) It has been previously used for treatment of some life-threatening infections such as Ebola virus, Lassa virus and rabies. Its therapeutic efficacy has been proven in these diseases.(36) Like, the antimalarials and antibiotics, favipiravir has no large-scale randomized trials completed at this time, given the short time frame of the pandemic. A dose administration could be 1600 mg po bid on day 1, following by 600 mg po bid for 14 days.(37)

Immunomodulators

The manifestations of COVID-19 that prompt hospitalization and that may well lead to multi-organ system failure are attributed to a cytokine storm. The characteristic profile of an acutely ill COVID-19 patient includes leukocytosis with a relative neutropenia. COVID-19 patients have higher serum level of cytokines (TNF- α , IFN- γ , IL-1 β , IL-2, IL-4, IL-6 and IL-10) and C-reactive protein than control individuals. Among COVID-19 patients, serum IL-6 and IL-10 levels appear even more elevated in the critically ill.(38) As with any acute inflammatory state, early treatment with immunomodulators is expected to impart greater benefit. In COVID-19, some of the first respiratory findings are nasal congestion, cough, and wheezing. These features are due to excess inflammation and cytokine activation. Early use of corticosteroids is a rational intervention for COVID-19 patients with these features as they would be in acute asthma or reactive airways disease.(39,40) The RECOVERY trial randomized 6425 hospitalized patients with COVID-19 in a 2:1 ratio to dexamethasone 6 mg po/IV qd for up to 10 days and found dexamethasone reduced mortality, HR=0.65, 95% CI 0.51-0.82, $p<0.001$.(41) One potential dosing scheme for outpatients starting on day five or the onset of respiratory symptoms is prednisone 1 mg/kg given daily for five days with or without a subsequent taper.

Colchicine

Colchicine is a non-steroidal anti-mitotic drug which blocks metaphase by binding to the ends of microtubules to prevent the elongation of the microtubule polymer. This agent has proven useful in gout and idiopathic recurrent pericarditis. The GRECCO-19 randomized open-label trial in 105 hospitalized patients with COVID-19, found that colchicine was associated with a reduction in D-dimer levels and improved clinical outcomes.(42) The clinical primary end point (2-point change in World Health Organization ordinal scale) occurred in 14.0% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; P = .02).(43) Because the short-term safety profile is well understood, it is reasonable to consider this agent along with corticosteroids in an attempt to reduce the effects of cytokine storm. A dosing scheme of 1.2 mg po, followed by 0.6 mg po bid for three weeks can be considered.

Antiplatelet Agents and Antithrombotics

Multiple studies have described increased rates of pathological macro and micro-thrombosis.(44,45) COVID-19 patients have described chest heaviness associated with desaturation that suggests the possibility of pulmonary thrombosis.(46) Multiple reports have described elevated D-dimer levels in acutely ill COVID-19 patients which has been consistently associated with increased risk of deep venous thrombosis and pulmonary embolism.(47,48,49) Necropsy studies have described pulmonary microthrombosis in COVID-19.(50) These observations support the notion that endothelial injury and thrombosis are playing a role oxygen desaturation, a cardinal reason for hospitalization and supportive care.(47) Based on this pathophysiologic rationale, aspirin 81 mg per

day can be administered as an initial antiplatelet and anti-inflammatory agent.(51,52) Ambulatory patients can be additionally treated with subcutaneous low-molecular weight heparin or with short-acting novel anticoagulant drugs in dosing schemes similar to those use in outpatient thromboprophylaxis. In a retrospective study of 2773 COVID-19 inpatients, 28% received anticoagulant therapy within 2 days of admission, and despite being used in more severe cases, anticoagulant administration was associated with a reduction in mortality, HR =0.86 per day of therapy, 95% CI: 0.82-0.89; $p < 0.001$. Additional supportive data on the use anticoagulants reducing mortality has been reported in hospitalized patients with elevated D-dimer levels and higher comorbidity scores.(53) Many acutely ill outpatients also have general indications for VTE prophylaxis applicable to COVID-19.(54)

Delivery of Oxygen and Monitoring

Because ambulatory centers and clinics have been reticent to have face-to-face visits for COVID-19 patients, telemedicine is a reasonable platform for monitoring. Clinical impressions can be gained with audio and video interviews by the physician with the patient. Supplemental information including vital signs and symptoms will be important to guide the physician. A significant component of safe outpatient management is maintenance of arterial oxygen saturation on room air or prescribed home oxygen under direct supervision by daily telemedicine with escalation to hospitalization for assisted ventilation if needed. Self-proning could be entertained for confident patients with good at-home monitoring.(55)

Many of the measures discussed in this paper could be extended to seniors in COVID-19 treatment units in nursing homes and other non-hospital settings. This would leave the purposes of hospitalization being administration of intravenous fluid and parenteral medication, assisted pressure or mechanical ventilation, and advanced mechanical circulatory support.

Summary

Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based upon pathophysiological principles. We have proposed an algorithm based on age and comorbidities that allows for a large proportion to be monitored and treated at home during self-isolation with the aim of reducing the risks of hospitalization and death.

Figure 1. Treatment algorithm for COVID-19 like and confirm COVID-19 illness in ambulatory patients at home in self-quarantine. Yr=year, BMI=body mass index, Dz=disease, DM=diabetes mellitus, CVD=cardiovascular disease, chronic kidney disease, HCQ=hydroxychloroquine, Mgt=management, Ox=oximetry

References

1. McCullough PA, Eidt J, Rangaswami J, et al. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection. *Rev Cardiovasc Med*. 2020;21(1):1-7. doi:10.31083/j.rcm.2020.01.42
2. Yang BY, Barnard LM, Emert JM, et al. Clinical Characteristics of Patients With Coronavirus Disease 2019 (COVID-19) Receiving Emergency Medical Services in King County, Washington. *JAMA Netw Open*. 2020;3(7):e2014549. Published 2020 Jul 1. doi:10.1001/jamanetworkopen.2020.14549
3. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. *BMJ*. 2020;369:m1996. Published 2020 May 29. doi:10.1136/bmj.m1996
4. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 18 March 2020. DOI: <http://dx.doi.org/10.15585/mmwr.mm6912e2>
5. <https://www.worldometers.info/coronavirus/> accessed July 3, 2020
6. <https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19> accessed July 3, 2020

7. <https://www.niaid.nih.gov/news-events/bulletin-nih-clinical-trial-evaluating-hydroxychloroquine-and-azithromycin-covid-19> accessed July 3, 2020
8. https://clinicaltrials.gov/ct2/who_table accessed July 3, 2020
9. Gopalakrishnan A, Mossaid A, Lo KB, Vasudevan V, McCullough PA, Rangaswami J. Fulminant Acute Kidney Injury in a Young Patient with Novel Coronavirus 2019 [published online ahead of print, 2020 May 6]. *Cardiorenal Med.* 2020;1-6. doi:10.1159/000508179
10. Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O'Donnell CJ, Warraich HJ. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States [published online ahead of print, 2020 May 28]. *JAMA.* 2020;323(24):2524-2526. doi:10.1001/jama.2020.9184
11. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/ccovidview/05152020/covid-like-illness.html> accessed July 3, 2020
12. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *Cochrane Database Syst Rev.* 2020;4(4):CD013574. Published 2020 Apr 8. doi:10.1002/14651858.CD013574
13. Xu XK, Liu XF, Wu Y, et al. Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection [published online ahead of print, 2020 Jun 18]. *Clin Infect Dis.* 2020;ciaa790. doi:10.1093/cid/ciaa790
14. Hsiang S, Allen D, Annan-Phan S, et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic [published online ahead of print, 2020 Jun 8]. *Nature.* 2020;10.1038/s41586-020-2404-8. doi:10.1038/s41586-020-2404-8

15. Chen LD. Effects of ambient temperature and humidity on droplet lifetime - A perspective of exhalation sneeze droplets with COVID-19 virus transmission [published online ahead of print, 2020 Jun 5]. *Int J Hyg Environ Health*. 2020;229:113568. doi:10.1016/j.ijheh.2020.113568
16. Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. *Kidney Int*. 2020 Jun;97(6):1297-1298. doi: 10.1016/j.kint.2020.03.015. Epub 2020 Mar 30. PMID: 32317113; PMCID: PMC7271263.
17. Shojaei A, Salari P. COVID-19 and off label use of drugs: an ethical viewpoint [published online ahead of print, 2020 May 8]. *Daru*. 2020;1-5. doi:10.1007/s40199-020-00351-y
18. Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2000;133(4):245-252. doi:10.7326/0003-4819-133-4-200008150-00006
19. Rahman MT, Iddid SZ. Can Zn Be a Critical Element in COVID-19 Treatment? [published online ahead of print, 2020 May 26]. *Biol Trace Elem Res*. 2020;1-9. doi:10.1007/s12011-020-02194-9
20. <https://docs.google.com/document/d/1pigHlql-ZuKOziN3txQsN5zz62v3K043pR3DdhEmcos/edit> accessed July 3, 2020
21. Te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog*. 2010;6(11):e1001176. Published 2010 Nov 4. doi:10.1371/journal.ppat.1001176

22. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020 May 11;323(24):2493–502. doi: 10.1001/jama.2020.8630. Epub ahead of print. PMID: 32392282; PMCID: PMC7215635.
23. Arshad S et al, Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19, Published: July 01, 2020 DOI: <https://doi.org/10.1016/j.ijid.2020.06.099>
24. Mikami T, Miyashita H, Yamada T, et al. Risk Factors for Mortality in Patients with COVID-19 in New York City [published online ahead of print, 2020 Jun 30]. *J Gen Intern Med*. 2020;1-10. doi:10.1007/s11606-020-05983-z
25. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol*. 2020;16(3):155-166. doi:10.1038/s41584-020-0372-x
26. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or> accessed July 3 2020
27. Pani A, Lauriola et al. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. *Int J Antimicrobial Agents*. June 2020. PMID: 32534189; doi: 10.1016/j.ijantimicag.2020.106053
28. Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis [published online ahead of print, 2020 Jun 25]. *Travel Med Infect Dis*. 2020;101791. doi:10.1016/j.tmaid.2020.101791

29. Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis.* 2020;35:101738.
doi:10.1016/j.tmaid.2020.101738
30. Risch HA. Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis [published online ahead of print, 2020 May 27]. *Am J Epidemiol.* 2020;kwaa093.
doi:10.1093/aje/kwaa093
31. Eljaaly K, Alshehri S, Aljabri A, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. *BMC Infect Dis.* 2017;17(1):385. Published 2017 Jun 2. doi:10.1186/s12879-017-2495-5
32. Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. *IDCases.* 2020;21:e00864. Published 2020 Jun 6.
doi:10.1016/j.idcr.2020.e00864
33. Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. *Pharmacotherapy* 2020;40(5):487–488) doi: 10.1002/phar.2395
34. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia. *Arch Intern Med.* 1999;159(3):266–270.
doi:10.1001/archinte.159.3.266
35. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19?. *J Antimicrob Chemother.* 2020;75(7):2013-2014. doi:10.1093/jac/dkaa171
36. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?. *J Virus Erad.* 2020;6(2):45-51. Published 2020 Apr 30.

37. Li J, Zhang C, Wu Z, Wang G, Zhao H. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020;21(1):488. Published 2020 Jun 5. doi:10.1186/s13063-020-04430-y
38. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect*. 2020;9(1):1123-1130. doi:10.1080/22221751.2020.1770129
39. Kolilekas L, Loverdos K, Giannakaki S, et al. Can steroids reverse the severe COVID-19 induced "cytokine storm"? [published online ahead of print, 2020 Jun 12]. *J Med Virol*. 2020;10.1002/jmv.26165. doi:10.1002/jmv.26165
40. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective [published online ahead of print, 2020 Jun 27]. *Diabetes Metab Syndr*. 2020;14(5):971-978. doi:10.1016/j.dsx.2020.06.054
41. <https://www.recoverytrial.net/results/dexamethasone-results>
42. Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. *JAMA Netw Open*. 2020;3(6):e2013136. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.13136
43. World Health Organization R&D blueprint and COVID-19. Accessed March 25, 2020. <https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/>
44. Bösmüller H, Traxler S, Bitzer M, et al. The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation [published

online ahead of print, 2020 Jun 30]. *Virchows Arch.* 2020;1-9.

doi:10.1007/s00428-020-02881-x

45. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications [published online ahead of print, 2020 Jun 26]. *Circ Res.* 2020;10.1161/CIRCRESAHA.120.317447.
doi:10.1161/CIRCRESAHA.120.317447
46. Bhandari S, Rankawat G, Bagarhatta M, et al. Clinico-Radiological Evaluation and Correlation of CT Chest Images with Progress of Disease in COVID-19 Patients. *J Assoc Physicians India.* 2020;68(7):34-42.
47. Chan KH, Slim J, Shaaban HS. Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease [published online ahead of print, 2020 Jul 2]. *Emerg Infect Dis.* 2020;26(10):10.3201/eid2610.202127.
doi:10.3201/eid2610.202127
48. Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. *J Thromb Thrombolysis.* 2020;50(1):211-216. doi:10.1007/s11239-020-02146-z
49. Mestre-Gómez B, Lorente-Ramos RM, Rogado J, et al. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis [published online ahead of print, 2020 Jun 29]. *J Thromb Thrombolysis.* 2020;10.1007/s11239-020-02190-9. doi:10.1007/s11239-020-02190-9
50. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 [published online ahead of print, 2020 May 21]. *N Engl J Med.* 2020;10.1056/NEJMoa2015432.
doi:10.1056/NEJMoa2015432

51. Turshudzhyan A. Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy. *Cureus*. 2020;12(5):e8150. Published 2020 May 16. doi:10.7759/cureus.8150
52. Glatthaar-Saalmüller B, Mair KH, Saalmüller A. Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study. *Influenza Other Respir Viruses*. 2017;11(1):85-92. doi:10.1111/irv.12421
53. Tang, N et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haem*. March 2020. Doi: 10.1111/jth.14817
54. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With COVID-19: CHEST Guideline and Expert Panel Report [published online ahead of print, 2020 Jun 2]. *Chest*. 2020;S0012-3692(20)31625-1. doi:10.1016/j.chest.2020.05.559
55. Westafer LM, Elia T, Medarametla V, Lagu T. A Transdisciplinary COVID-19 Early Respiratory Intervention Protocol: An Implementation Story. *J Hosp Med*. 2020;15(6):372-374. doi:10.12788/jhm.3456




Figure 1 COVID-19 Outpatient Treatment Algorithm